Business Context and Reporting Period
This Form 8-K was filed by Novus Therapeutics, Inc. on March 9, 2018. The report addresses the conclusion of the company's "at-the-market" (ATM) offering facility for common stock, originally established under a prospectus dated August 21, 2017.
Key Financial Metrics
- Capital Raised: Approximately $8.5 million in aggregate gross offering proceeds.
- Shares Issued: 2,463,966 shares of common stock sold under the prospectus since September 30, 2017.
- Outstanding Shares: 9,407,024 shares of common stock issued and outstanding as of the filing date.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels.
Material Changes
The primary material change is the termination of the ATM offering program. Consequently, no further sales of common stock will be made pursuant to the August 21, 2017 prospectus. This action increased the company's share count by approximately 35% relative to the pre-offering period (based on the 2.46 million shares issued against the remaining balance).
Outlook and Management Commentary
Management, represented by CEO Gregory J. Flesher, confirmed the conclusion of the offering. The filing does not contain forward-looking guidance, risk factor updates, or commentary on future operational plans beyond the cessation of this specific capital raise mechanism.
Investor Verification Checklist
- Verify the current cash balance and burn rate to assess runway following the $8.5 million raise.
- Confirm the exact share count prior to September 30, 2017, to validate the dilution impact.
- Review subsequent filings to determine if a new capital raise mechanism has been initiated.
- Check for any outstanding debt or convertible notes not detailed in this specific 8-K.